Sevahn K. Vorperian

Sevahn K. Vorperian

Auto-generated profile, based on publicly available information

Sevahn K. Vorperian

Department of Chemical Engineering, Stanford University, Stanford, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in Nature
Verified
Journal Article
Open access
PDF file
MMMira N. Moufarrej
Mira N. Moufarrej
SVSevahn K. Vorperian
Sevahn K. Vorperian
RWRonald Wong
Ronald Wong
ACAna A. Campos
Ana A. Campos
CQCecele C. Quaintance
Cecele C. Quaintance
SQStephen Quake
Stephen Quake
Liquid biopsies that measure circulating cell-free RNA (cfRNA) offer an opportunity to study the development of pregnancy-related complications in a non-invasive manner and to bridge gaps in clinical care1–4. Here we used 404 blood samples from 199 pregnant mothers to identify and validate cfRNA transcriptomic changes that are associated with preeclampsia, a multi-organ syndrome that is the second largest cause of maternal death globally5. We find that changes in cfRNA gene expression between normotensive and preeclamptic mothers are marked and stable early in gestation, well before the onset of symptoms. These changes are enriched for genes specific to neuromuscular, endothelial and immune cell types and tissues that reflect key aspects of preeclampsia physiology6–9, suggest new hypotheses for disease progression and correlate with maternal organ health. This enabled the identification and independent validation of a panel of 18 genes that when measured between 5 and 16 weeks of gestation can form the basis of a liquid biopsy test that would identify mothers at risk of preeclampsia long before clinical symptoms manifest themselves. Tests based on these observations could help predict and manage who is at risk for preeclampsia—an important objective for obstetric care10,11.

7 February 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
SVSevahn K. Vorperian
Sevahn K. Vorperian
MMMira N. Moufarrej
Mira N. Moufarrej
SQStephen Quake
Stephen Quake
Cell-free RNA from liquid biopsies can be analyzed to determine disease tissue of origin. We extend this concept to identify cell types of origin using the Tabula Sapiens transcriptomic cell atlas as well as individual tissue transcriptomic cell atlases in combination with the Human Protein Atlas RNA consensus dataset. We define cell type signature scores, which allow the inference of cell types that contribute to cell-free RNA for a variety of diseases.

5 May 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
SVSevahn K. Vorperian
Sevahn K. Vorperian
MMMira N. Moufarrej
Mira N. Moufarrej
TCTabula Sapiens Consortium
Tabula Sapiens Consortium
SQStephen Quake
Stephen Quake
Cell-free RNA (cfRNA) can be used to noninvasively measure dynamic and longitudinal physiological changes throughout the body. While there is considerable effort in the liquid biopsy field to determine disease tissue-of-origin, pathophysiology occurs at the cellular level. Here, we describe two approaches to identify cell type contributions to cfRNA. First we used Tabula Sapiens , a transcriptomic cell atlas of the human body to computationally deconvolve the cell-free transcriptome into a sum of cell type specific transcriptomes, thus revealing the spectrum of cell types readily detectable in the blood. Second, we used individual tissue transcriptomic cell atlases in combination with the Human Protein Atlas RNA consensus dataset to create cell type signature scores which can be used to infer the implicated cell types from cfRNA for a variety of diseases. Taken together, these results demonstrate that cfRNA reflects cellular contributions in health and disease from diverse cell types, potentially enabling determination of pathophysiological changes of many cell types from a single blood test.

26 November 2025 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
SVSevahn K. Vorperian
Sevahn K. Vorperian
LDLucas M. Dennis
Lucas M. Dennis
AHAnna Hupalowska
Anna Hupalowska
JRJennifer E. Rood
Jennifer E. Rood
SQStephen Quake
Stephen Quake

28 March 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
SVSevahn K. Vorperian
Sevahn K. Vorperian
MMMira N. Moufarrej
Mira N. Moufarrej
SQStephen Quake
Stephen Quake